• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Genelux Corporation

    3/19/26 5:27:03 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GNLX alert in real time by email
    S-8 1 forms-8.htm S-8

     

    As filed with the Securities and Exchange Commission on March 19, 2026

     

    Registration No. 333-

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER THE SECURITIES ACT OF 1933

     

     

     

    GENELUX CORPORATION

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   77-0583529
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification No.)
         

    2625 Townsgate Road, Suite 230

    Westlake Village, California 91361

      91361
    (Address of Principal Executive Offices)   (Zip Code)

     

    2022 Equity Incentive Plan

    2022 Employee Stock Purchase Plan

    (Full title of the plans)

     

    Thomas Zindrick, J.D.

    President and Chief Executive Officer

    Genelux Corporation

    2625 Townsgate Road, Suite 230

    Westlake Village, California 91361

    (805) 267-9889

    (Name, address, and telephone number, including area code, of agent for service)

     

     

     

    Copies to:

     

    Jason L. Kent

    Christine S. Kim

    Cooley LLP

    10265 Science Center Drive

    San Diego, California 92121

    (858) 550-6000

     

     

     

    Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
           
    Non-accelerated filer ☒ Smaller reporting company ☒
           
        Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 (the “Registration Statement”) is being filed by Genelux Corporation (the “Registrant”) for the purpose of registering (i) an additional 1,906,957 shares of Registrant’s common stock, par value $0.001 per share (the “Common Stock”), under the Registrant’s 2022 Equity Incentive Plan (the “2022 Plan”) pursuant to the provisions for the 2022 Plan providing for an automatic increase in the number of shares of Common Stock reserved and available for issuance under the 2022 Plan and (ii) an additional 381,391 shares of Registrant’s Common Stock under the Registrant’s 2022 Employee Stock Purchase Plan (the “2022 ESPP” and together with the 2022 Plan, the “Plans”) pursuant to the provisions for the 2022 ESPP providing for an automatic increase in the number of shares of Common Stock reserved and available for issuance under the 2022 ESPP, in each case on January 1, 2026.

     

    Pursuant to General Instruction E of Form S-8, this Registration Statement incorporates by reference the contents of the registration statements on Form S-8 relating to the Plans filed by the Registrant with the Securities and Exchange Commission (the “SEC”) on January 26, 2023 (File No. 333-269427), March 29, 2024 (File No. 333-278372) and March 28, 2025 (File No. 333-286223) (collectively, the “Prior Registration Statements”), except that the provisions contained in Part II of such Prior Registration Statements are modified or supplemented, as the case may be, as set forth in this registration statement.

     

     

     

     

    PART II

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents filed by the Registrant with the SEC are incorporated by reference into this Registration Statement:

     

    (a) the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 19, 2026;
       
    (b) the Registrant’s Current Report on Form 8-K filed with the SEC on January 2, 2026, January 5, 2026, January 8, 2026 and March 19, 2026 (each to the extent the information in such reports is filed and not furnished); and
       
    (c) the description of the Registrant’s Common Stock contained in the Registrant’s registration statement on Form 8-A, filed with the SEC on January 23, 2023, including any amendments or reports filed for the purpose of updating such description, including Exhibit 4.16 of the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 28, 2025.

     

    All reports and other documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, other than Current Reports furnished under Item 2.02 or Item 7.01 of exhibits furnished on such form that relate to items and other portions of documents that are furnished but not filed or are otherwise not incorporated into registration statements pursuant to the applicable rules promulgated by the SEC, after the date of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement herein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not constitute a part of this Registration Statement, except as so modified or superseded.

     

     

     

     

    Item 8. Exhibits.

     

    The exhibits to this Registration Statement are listed below:

     

    Exhibit

    Number

      Description
         
    4.1   Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-41599), filed with the SEC on January 30, 2023).
         
    4.2   Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No. 001-41599), filed with the SEC on January 30, 2023).
         
    4.3   Form of Common Stock Certificate (incorporated herein by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-265828), filed with the SEC on August 29, 2022).
         
    4.4   Form of Representative’s Warrant (incorporated herein by reference to Exhibit 4.7 to the Amendment No. 2 of Form S-1(File No. 333-265828), filed with the SEC on September 19, 2022).
         
    4.5   Form of Underwriter Warrant dated March 26, 2025 (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K (File No. 001-41599), filed with the SEC on March 25, 2025).
         
    4.6   Form of Warrant (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K (File No. 001-41599), filed with the SEC on May 24, 2024).
         
    5.1*   Opinion of Cooley LLP.
         
    23.1*   Consent of Weinberg & Company, P.A., independent registered public accounting firm.
         
    23.2*   Consent of Cooley LLP (included in Exhibit 5.1).
         
    24.1*   Power of Attorney (included on the signature page hereto).
         
    99.1   Genelux Corporation 2022 Equity Incentive Plan (incorporated by reference to Exhibit 10.5 to the Registrant’s Registration Statement on Form S-1 (File No. 333-265828), as amended, filed with the SEC on January 10, 2023).
         
    99.2   Forms of Grant Notice, Stock Option Agreement and Notice of Exercise under the Genelux Corporation 2022 Equity Incentive Plan (incorporated by reference to Exhibit 10.6 to the Registrant’s Registration Statement on Form S-1 (File No. 333-265828), as amended, originally filed with the SEC on June 24, 2022).
         
    99.3   Genelux Corporation 2022 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.7 to the Registrant’s Registration Statement on Form S-1 (File No. 333-265828), as amended, filed with the SEC on January 10, 2023).
         
    107*   Filing Fee Table.

     

    * Filed herewith

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Westlake Village, State of California, on March 19, 2026.

     

      GENELUX CORPORATION
         
      By:

    /s/ Thomas Zindrick, J.D.

        Thomas Zindrick, J.D.
        President and Chief Executive Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Thomas Zindrick, J.D. and Matthew Pulisic as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in their name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to sign any registration statement for the same offering covered by this registration statement that is to be effective on filing pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and all post-effective amendments thereto, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Thomas Zindrick, J.D.   President, Chief Executive Officer and Chairman of the Board   March 19, 2026
    Thomas Zindrick, J.D.   (Principal Executive Officer)    
             
    /s/ Matthew Pulisic   Chief Financial Officer   March 19, 2026
    Matthew Pulisic   (Principal Financial and Accounting Officer)    
             
    /s/ Mary Mirabelli   Director   March 19, 2026
    Mary Mirabelli        
             
    /s/ James L. Tyree   Director   March 19, 2026
    James L. Tyree        
             
    /s/ John Smither   Director   March 19, 2026
    John Smither        
             
    /s/ John Thomas, Ph.D.   Director   March 19, 2026
    John Thomas, Ph.D.        

     

     

     

     

    Get the next $GNLX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GNLX

    DatePrice TargetRatingAnalyst
    10/21/2025$16.00Buy
    Lake Street
    10/29/2024$8.00Buy
    Guggenheim
    8/28/2024$10.00Buy
    ROTH MKM
    11/27/2023$35.00Buy
    H.C. Wainwright
    9/12/2023$40.00Buy
    Maxim Group
    2/15/2023$10.00Speculative Buy
    The Benchmark Company
    More analyst ratings

    $GNLX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

    -- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Interim systemic lung cancer data with Olvi-Vec demonstrated partial responses in relapsed small cell lung cancer (SCLC) and early signs of anti-tumor activity in non-small cell lung cancer (NSCLC); additional updates expected throughout 2026 -- -- Appointed Jason Litten, M.D., as Chief Medical Officer to lead clinical development strategy -- -- $33.1 million in pro forma cash, cash equivalents, marketable securities and restricted cash as of December 31, 2025, including $18.5 million in net proceeds from underwritten offering of common stock in January 2026; expected to su

    3/19/26 4:15:00 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genelux Corporation to Participate in Upcoming Conferences

    WESTLAKE VILLAGE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that the Company will participate in two upcoming conferences. Oppenheimer Healthcare Life Sciences Conference: Thomas Zindrick, President, CEO and Chairman of the Board; Matt Pulisic, Chief Financial Officer; and Dr. Jason Litten, Chief Medical Officer, will participate in a virtual fireside chat on Wednesday, February 25, 2026, at 11:20 a.m. ET.TD Cowen 46th Annual Health Care Conference: Thomas Zindrick, President, CEO and Chairman of the Board, and Matt Pulisic, Chief Financial Officer, will participate in a presentation on Monda

    2/18/26 8:00:00 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners

    WESTLAKE VILLAGE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board; Matt Pulisic, Chief Financial Officer; and Dr. Jason Litten, Chief Medical Officer, will participate in a virtual fireside chat hosted by Boris Peaker, PhD, Managing Director and Senior Equity Research Analyst at Titan Partners, on Monday, January 19, 2026 at 9:00 a.m. PT. A live webcast of the fireside chat can be found here and on the investor relations section of the Company's website at https://investors.genelux.com/. Following the live webcast, an archived replay wi

    1/12/26 4:00:00 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Thomas John sold $28,957 worth of shares (10,000 units at $2.90), decreasing direct ownership by 2% to 482,784 units (SEC Form 4)

    4 - GENELUX Corp (0001231457) (Issuer)

    3/3/26 8:05:01 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Medical Officer Litten Jason

    4 - GENELUX Corp (0001231457) (Issuer)

    1/7/26 5:32:02 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Litten Jason

    3 - GENELUX Corp (0001231457) (Issuer)

    1/7/26 5:30:31 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Genelux with a new price target

    Lake Street initiated coverage of Genelux with a rating of Buy and set a new price target of $16.00

    10/21/25 7:59:44 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Genelux with a new price target

    Guggenheim initiated coverage of Genelux with a rating of Buy and set a new price target of $8.00

    10/29/24 6:26:41 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ROTH MKM initiated coverage on Genelux with a new price target

    ROTH MKM initiated coverage of Genelux with a rating of Buy and set a new price target of $10.00

    8/28/24 7:46:18 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNLX
    SEC Filings

    View All

    SEC Form 424B5 filed by Genelux Corporation

    424B5 - GENELUX Corp (0001231457) (Filer)

    3/19/26 5:30:03 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Genelux Corporation

    S-8 - GENELUX Corp (0001231457) (Filer)

    3/19/26 5:27:03 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genelux Corporation filed SEC Form 8-K: Financial Statements and Exhibits

    8-K - GENELUX Corp (0001231457) (Filer)

    3/19/26 4:52:48 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNLX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Tyree James L bought 6,250 shares, increasing direct ownership by 181% to 9,710 units (SEC Form 4)

    4 - GENELUX Corp (0001231457) (Issuer)

    6/7/24 9:45:20 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Thomas John bought 2,500 shares, increasing direct ownership by 0.54% to 465,960 units (SEC Form 4)

    4 - GENELUX Corp (0001231457) (Issuer)

    6/7/24 9:45:16 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Smither John W bought 6,250 shares, increasing direct ownership by 90% to 13,170 units (SEC Form 4)

    4 - GENELUX Corp (0001231457) (Issuer)

    6/7/24 9:45:18 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNLX
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Does the Recent Purchase at Air Transport Services Group Inc on Jun 7 Indicate?

    Recently, on June 7, 2024, Michael L Berger, a significant figure at Air Transport Services Group Inc, made a notable insider purchase. Berger bought $49,830 worth of shares, acquiring 3,996 units at a price of $12.47 per share. This transaction increased his direct ownership by 4% to 103,705 units as reported in the SEC Form 4 here. Examining other insider actions within the company can sometimes reveal intriguing patterns that might offer insights for investors. Looking back at previous transactions, we see a series of insider activities at Air Transport Services Group Inc: In March 2024, Dominick Jeffrey A. filed an SEC Form 4, indicating a notable transaction date in which actions were

    6/10/24 12:35:45 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNLX
    Leadership Updates

    Live Leadership Updates

    View All

    Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer

    WESTLAKE VILLAGE, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) --  Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Jason Litten, M.D., as Chief Medical Officer, effective January 2, 2026. Dr. Litten will oversee all clinical development and medical strategy as the company advances Olvi-Vec through multiple upcoming pivotal milestones. "We are excited to welcome Jason, who is widely recognized for his strategic approach to clinical development and commitment to improving patient outcomes," said Thomas Zindrick, President, CEO, and Chairman of the Board. "He brings extensive experience in oncology drug development of innovati

    1/2/26 8:00:00 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates

    WESTLAKE VILLAGE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter of 2025 and provided general business updates. Momentum continued to build across the Company, as it looks forward to a series of key clinical readouts over the next year. These readouts are intended to further demonstrate the ability of Olvi-Vec to resensitize tumors to frontline platinum-based regimens. Genelux continues to advance Olvi-Vec toward potential registration in platinum-resistant/refractory ovarian cancer (PRROC) with topline data expected in the first half of 2026. Earlier this

    8/7/25 4:20:00 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development

    WESTLAKE VILLAGE, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development, effective July 1, 2025. "We are delighted to welcome Eric to the executive team," said Thomas Zindrick, President, CEO, and Chairman of the Board. "Eric brings a powerful blend of legal expertise, global business development savvy, and a strategic understanding of the biotechnology ecosystem. His proven ability to lead high-impact transactions, build trusted partnerships, and navigate complex regulatory

    7/7/25 7:00:00 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Genelux Corporation

    SC 13G - GENELUX Corp (0001231457) (Subject)

    10/25/24 9:45:20 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Genelux Corporation

    SC 13G/A - GENELUX Corp (0001231457) (Subject)

    10/22/24 4:12:19 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Genelux Corporation

    SC 13G - GENELUX Corp (0001231457) (Subject)

    2/2/24 4:06:25 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care